Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19 : Review of the Literature
Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2). The US Food and Drug Administration (FDA) and the European Medical Agency (EMA) have already authorized monoclonal antibodies of anti-SARS-CoV-2 to treat mild to moderate CoronaVIrus Disease-2019 (COVID-19) in patients at risk of developing severe disease. More recently, monoclonal antibodies anti-SARS-CoV-2 have been authorized for primary and secondary prophylaxis in patients at high risk of severe disease for background comorbidity. Primary or pre-exposure prophylaxis prevents COVID-19 in unexposed people, whereas secondary or postexposure prophylaxis prevent COVID-19 in recently exposed people to individuals with laboratory-confirmed SARS-CoV-2. This review focuses briefly on therapeutic indications of currently available monoclonal antibodies for COVID-19 pre- and postexposure prophylaxis and on the efficacy of convalescent plasma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Pathogens (Basel, Switzerland) - 11(2022), 8 vom: 05. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vita, Serena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 30.08.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/pathogens11080882 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345333985 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345333985 | ||
| 003 | DE-627 | ||
| 005 | 20231226024831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pathogens11080882 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345333985 | ||
| 035 | |a (NLM)36015003 | ||
| 035 | |a (PII)882 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vita, Serena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19 |b Review of the Literature |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.08.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2). The US Food and Drug Administration (FDA) and the European Medical Agency (EMA) have already authorized monoclonal antibodies of anti-SARS-CoV-2 to treat mild to moderate CoronaVIrus Disease-2019 (COVID-19) in patients at risk of developing severe disease. More recently, monoclonal antibodies anti-SARS-CoV-2 have been authorized for primary and secondary prophylaxis in patients at high risk of severe disease for background comorbidity. Primary or pre-exposure prophylaxis prevents COVID-19 in unexposed people, whereas secondary or postexposure prophylaxis prevent COVID-19 in recently exposed people to individuals with laboratory-confirmed SARS-CoV-2. This review focuses briefly on therapeutic indications of currently available monoclonal antibodies for COVID-19 pre- and postexposure prophylaxis and on the efficacy of convalescent plasma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 4 | |a prophylaxis | |
| 700 | 1 | |a Rosati, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Ascoli Bartoli, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Beccacece, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Abramo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Mariano, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Scorzolini, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 700 | 1 | |a Nicastri, Emanuele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathogens (Basel, Switzerland) |d 2011 |g 11(2022), 8 vom: 05. Aug. |w (DE-627)NLM22512761X |x 2076-0817 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:8 |g day:05 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/pathogens11080882 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 8 |b 05 |c 08 | ||